Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2018 · 10-Q
Revenue$5.75M$5.75M+36.9% vs Q3 2017 Net Income-$3.13M-$3.13MN/M vs Q3 2017 EPS Diluted-$0.11-$0.11N/M vs Q3 2017 Gross Profit$2,990,000+40.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,773,000N/M Free Cash Flowderived-$2,082,000— Margins · derivedGross margin52.0%+1.2 pt vs Q3 2017
Operating margin-42.8%+30.8 pt vs Q3 2017
Net margin-54.3%+26.6 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end